These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 36362912)
1. A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. Haddad F; Dokmak G; Karaman R Life (Basel); 2022 Nov; 12(11):. PubMed ID: 36362912 [TBL] [Abstract][Full Text] [Related]
8. Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients. Yetmar ZA; Bhaimia E; Razonable RR Curr Opin Organ Transplant; 2022 Aug; 27(4):269-276. PubMed ID: 36354253 [TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study. Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E; Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429 [TBL] [Abstract][Full Text] [Related]
10. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019. Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review. Ravi G; Eerike M; Konda VR; Bisoi D; Raj GM; Priyadarshini R; Mali KR; Chaliserry LF Monoclon Antib Immunodiagn Immunother; 2023 Apr; 42(2):77-94. PubMed ID: 37129306 [TBL] [Abstract][Full Text] [Related]
12. Increased reporting of venous and arterial thromboembolic events reported with tixagevimab-cilgavimab for coronavirus disease 2019. Montastruc F; Lafaurie M; Flumian C; de Canecaude C Clin Microbiol Infect; 2023 Apr; 29(4):543.e1-543.e3. PubMed ID: 36464214 [TBL] [Abstract][Full Text] [Related]
13. Current Effective Therapeutics in Management of COVID-19. Atluri K; Aimlin I; Arora S J Clin Med; 2022 Jul; 11(13):. PubMed ID: 35807123 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19. Zou J; Jing F Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558922 [TBL] [Abstract][Full Text] [Related]
15. COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients. Bellino S Ann Med; 2022 Dec; 54(1):2856-2860. PubMed ID: 36259490 [TBL] [Abstract][Full Text] [Related]
16. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. Siemieniuk RA; Bartoszko JJ; Díaz Martinez JP; Kum E; Qasim A; Zeraatkar D; Izcovich A; Mangala S; Ge L; Han MA; Agoritsas T; Arnold D; Ávila C; Chu DK; Couban R; Cusano E; Darzi AJ; Devji T; Foroutan F; Ghadimi M; Khamis A; Lamontagne F; Loeb M; Miroshnychenko A; Motaghi S; Murthy S; Mustafa RA; Rada G; Rochwerg B; Switzer C; Vandvik PO; Vernooij RW; Wang Y; Yao L; Guyatt GH; Brignardello-Petersen R BMJ; 2021 Sep; 374():n2231. PubMed ID: 34556486 [TBL] [Abstract][Full Text] [Related]
17. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drożdżal S; Rosik J; Lechowicz K; Machaj F; Szostak B; Przybyciński J; Lorzadeh S; Kotfis K; Ghavami S; Łos MJ Drug Resist Updat; 2021 Dec; 59():100794. PubMed ID: 34991982 [TBL] [Abstract][Full Text] [Related]